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Inflammation develops in response to foreign 
agents or injuries and is crucial to the healing 
process. However, persistent unresolved inflam­
mation can contribute to the development of can­
cer (Coussens et al., 2013). Despite the wealth of 
information implicating inflammation in tumor 
development, the specific role of different cells, 
especially myeloid cells, in this process remains 
largely unclear. Myeloid cells are an important 
component of inflammation. There is now ample 
evidence of abnormalities in the myeloid com­
partment in cancer, which manifests in inhi­
bition of differentiation of DCs, polarization 
of macrophages (Ms) toward M2 functional 
state, and dramatic expansion of myeloid­derived 
suppressor cells (MDSCs; Gabrilovich et al., 2012). 
MDSCs represent a heterogeneous population 
of pathologically activated myeloid cells that 
includes precursors of neutrophils (polymorpho­
nuclear neutrophils [PMNs]), Ms, DCs, and 
cells at earlier stages of myeloid cell differentia­
tion (Gabrilovich and Nagaraj, 2009; Peranzoni 
et al., 2010; Youn et al., 2012). In mice, these 
cells are defined as Gr­1+CD11b+ cells with the 
CORRESPONDENCE  
Dmitry Gabrilovich:  
dgabrilovich@wistar.org
Abbreviations used: BCC, basal 
cell carcinoma; DMBA, 7,12­
dimethylbenz(a)anthracene; IHC, 
immunohistochemistry; IMC, 
immature myeloid cell; LC, 
Langerhans cell; MDSC, myeloid­
derived suppressor cell; M, 
macrophage; PMN, polymorpho­
nuclear neutrophil; TPA, 12­O­
tetradecanoylphorbol­13­acetate.
*M.L. Ortiz, V. Kumar, and A. Martner contributed equally 
to this paper.
Immature myeloid cells directly contribute 
to skin tumor development by recruiting  
IL-17–producing CD4+ T cells
Myrna L. Ortiz,1* Vinit Kumar,2* Anna Martner,1,3* Sridevi Mony,2 
Laxminarasimha Donthireddy,2 Thomas Condamine,2 John Seykora,4  
Stella C. Knight,5 George Malietzis,5,6 Gui Han Lee,5,6 Morgan Moorghen,6 
Brianna Lenox,1,3 Noreen Luetteke,1 Esteban Celis,7  
and Dmitry Gabrilovich2
1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612
2The Wistar Institute, Philadelphia, PA 19104
3Sahlgrenska Cancer Center, University of Gothenburg, S-405 30 Gothenburg, Sweden
4Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104
5Antigen Presentation Research Group, Imperial College London, London HA1 3UJ, England, UK
6St. Mark’s Hospital, Harrow HA1 3UJ, England, UK
7Cancer Immunology, Inflammation, and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA 30912
Evidence links chronic inflammation with cancer, but cellular mechanisms involved in this 
process remain unclear. We have demonstrated that in humans, inflammatory conditions 
that predispose to development of skin and colon tumors are associated with accumulation 
in tissues of CD33+S00A9+ cells, the phenotype typical for myeloid-derived suppressor 
cells in cancer or immature myeloid cells (IMCs) in tumor-free hosts. To identify the direct 
role of these cells in tumor development, we used S00A9 transgenic mice to create the 
conditions for topical accumulation of these cells in the skin in the absence of infection or 
tissue damage. These mice demonstrated accumulation of granulocytic IMCs in the skin 
upon topical application of 2-O-tetradecanoylphorbol-3-acetate (TPA), resulting in a 
dramatic increase in the formation of papillomas during epidermal carcinogenesis. The 
effect of IMCs on tumorigenesis was not associated with immune suppression, but with 
CCL4 (chemokine [C-C motif] ligand 4)-mediated recruitment of IL-7–producing CD4+  
T cells. This chemokine was released by activated IMCs. Elimination of CD4+ T cells or 
blockade of CCL4 or IL-7 abrogated the increase in tumor formation caused by myeloid 
cells. Thus, this study implicates accumulation of IMCs as an initial step in facilitation of 
tumor formation, followed by the recruitment of CD4+ T cells.
© 2015 Ortiz et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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RESULTS
S00A9-positive myeloid cells in tissues of patients  
with inflammation or cancers
Although parameters for detection of MDSCs in peripheral 
blood of cancer patients by flow cytometry are well estab­
lished, immunohistochemical detection of these cells in 
tissues has not been developed. Thus, we designed a double­
staining protocol of tissues for the CD33 myeloid marker and 
S100A9 using confocal microscopy (Fig. 1 A). S100A9 was 
used for MDSC detection because this protein is directly im­
plicated in accumulation of these cells in cancer and is shown 
as an MDSC marker in peripheral blood of cancer patients. 
The presence of CD33+S100A9+ was then assessed in skin of 
patients with melanoma and basal cell carcinoma (BCC), as 
well as in patients with several inflammatory skin diseases 
(Fig. 1 B). No increase in the presence of these cells was found 
in patients with lichen planus or psoriasis as compared with 
controls. In contrast, patients with spongiotic dermatitis (ec­
zema) had significantly (P = 0.001) higher numbers of CD33+ 
S100A9+ cells in skin. The presence of these cells was a little 
higher in patients with BCC. Patients with melanoma had a 
dramatic increase in number of these cells (Fig. 1 C). CD33+ 
S100A9+ cells can represent not only IMCs or MDSCs but 
also PMNs because the expression of S100A9 is retained 
in these cells as opposed to Ms or DCs (Leder et al., 1990; 
Ehrchen et al., 2009; Srivastava et al., 2012; Markowitz and 
Carson, 2013). Therefore, we evaluated the presence of PMNs 
in skin using a specific marker neutrophil elastase. No differ­
ence in the number of PMNs was found for any of the condi­
tions except in patients with melanoma (Fig. 1 C). CD163+ 
Ms were modestly increased in skin of patients with ec­
zema, BCC, and melanoma (Fig. 1 C). We also evaluated colon 
tissue samples from a cohort of patients with ulcerative colitis 
with evidence of dysplasia and colon from cancer patients. 
Dramatic (>10­fold) increase in the presence of CD33+S100A9+ 
cells was found in tissues from patients with colitis and colon 
cancer, whereas the number of PMNs and Ms increased less 
than twofold (Fig. 1 E). Lichen planus and psoriasis are not 
associated with the development of skin cancer, whereas his­
tory of eczema is an independent predictor of BCC (Dyer 
et al., 2012). Ulcerative colitis, especially in patients with dys­
plasia, is associated with colon cancer (Dalgleish and O’Byrne, 
2006; Dyson and Rutter, 2012). These results indicate that the 
population of CD33+S100A9+ cells represented by IMCs or 
MDSCs is dramatically increased in select inflammatory con­
ditions, which are associated with an increased risk for devel­
oping cancer.
The role of IMCs in tumor development
Next we asked what role, if any, these cells can play in tumor 
development. To address this question, we used mice with 
overexpression of S100A9 protein in hematopoietic cells 
(S100A9Tg mice; Cheng et al., 2008). S100A9Tg mice (FVB/N 
background) had no detectable abnormalities during the first 
months of life (Chen et al., 2013). Compared with WT mice, 
S100A9Tg mice expressed higher amounts of S100A9 protein 
recognition of polymorphonuclear (PMN­MDSC) and mono­
nuclear (M­MDSC) subsets based on the expression of Ly6C 
and Ly6G markers (Fridlender et al., 2009; Peranzoni et al., 
2010; Brandau et al., 2011; Youn et al., 2012). MDSCs are char­
acterized by a potent immune­suppressive activity and the 
ability to promote tumor angiogenesis, tumor cell invasion, 
and metastases (Bierie and Moses, 2010; Gabrilovich et al., 
2012; Talmadge and Gabrilovich, 2013). In tumor­free mice, 
cells with the same phenotype represent immature myeloid 
cells (IMCs) lacking immune­suppressive activity. Expansion 
of MDSCs is considered a consequence of tumor progression. 
However, in recent years, it has become clear that the cells 
with phenotypes and functions attributed to MDSCs are 
readily detectable in different conditions associated with chronic 
inflammation not directly linked to cancer (Cuenca et al., 
2011; Nagaraj et al., 2013). We hypothesize that these cells can 
contribute to tumor development associated with inflamma­
tion. Understanding the role of specific components of 
inflammation in tumor development is difficult because of 
the fact that inflammation is a multicomponent complex pro­
cess. To address this question, we focused on S100A9 protein. 
This is the member of the S100 family of Ca2+­binding pro­
teins with diverse biological activity, including chemotaxis of 
myeloid cells, fatty acid transport, production of reactive oxy­
gen species, etc. (Markowitz and Carson, 2013). Expression of 
S100A9 together with its dimerization partner S100A8 is 
found predominantly in cells of the myeloid lineage. Differ­
entiation of myelocytes/granulocytes is associated with an 
increase of S100A8/A9 expression, whereas differentiation 
of Ms and DCs is associated with loss of their expression 
(Leder et al., 1990; Ehrchen et al., 2009; Srivastava et al., 2012; 
Markowitz and Carson, 2013). Cells of the lymphoid lineage 
do not express these proteins. We and others have previously 
found that accumulation of MDSCs and inhibition of DC 
differentiation in cancer were closely associated with up­ 
regulation of S100A8/A9 (Cheng et al., 2008; Sinha et al., 
2008; Ichikawa et al., 2011). The expansion of MDSCs was 
significantly reduced in S100A9­deficient mice treated with 
complete Freund’s adjuvant or tumor­bearing mice (Cheng 
et al., 2008). In contrast, overexpression of S100A9 in mice 
resulted in accumulation of cells with MDSC phenotype 
(Chen et al., 2013). Furthermore, these data were consistent 
with a recent report that DCs derived from S100A9­deficient 
mice induced stronger response of allogeneic T cells (Shimizu 
et al., 2011). In recent years, S100A9 was identified as a marker 
of MDSCs in peripheral blood of cancer patients and tumor­
bearing mice (Feng et al., 2012; Källberg et al., 2012; Zhao 
et al., 2012). We asked whether regulation of S100A9 level in 
myeloid cells could be used to dissect the possible role of 
MDSCs during early stages of tumor development. Here, we 
report that cells with the MDSC phenotype accumulate in 
tissues of patients with precancerous inflammation and that 
these cells play a major role in tumor development in mice. 
Importantly, this effect was not directly mediated by immune­
suppressive mechanisms but by the recruitment of IL­17– 
producing CD4+ T cells.
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Figure . Myeloid cells in human tissues. (A) Example of staining of melanoma with CD33 and S100A9 antibody. (B) Typical example of staining of 
tissues from patients with different skin pathologies. (C) The number of different myeloid cells in skin. Each group included five patients. (D) Typical  
example of staining of tissues from patients with colitis and colon cancer. (A, B, and D) Bars, 50 µm. (E) The number of different myeloid cells in colonic 
tissues. Control and colon cancer groups included six patients and colitis group included five patients. (C and E) Mean and SD are shown. The differences 
from control: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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a malignant stage (Humble et al., 2005). In C57BL/6 mice, 
skin tumor formation was induced by a single application of 
the carcinogen 7,12­dimethylbenz(a)anthracene (DMBA), fol­
lowed by 12­wk topical treatment with TPA.
Topical treatment of WT mice with TPA for 4 wk did 
not result in detectable levels of S100A9 in skin. In contrast, 
in BM, spleen, LNs, and lung, but not in skin or liver (Fig. 2 A). 
Two models of skin carcinogenesis were used. Tg.AC mice 
(also FVB/N) express the mutant v-h-ras transgene under the 
­globin promoter. When treated topically with the tumor 
promoter 12­O­tetradecanoylphorbol­13­acetate (TPA), Tg.AC 
mice develop multiple papillomas, some of which progress to 
Figure 2. Accumulation of IMCs in skin of 
S00A9Tg mice. (A) Amount of S100A9 protein in 
various organs of WT and S100A9Tg mice. Typical 
example of Western blotting of 30 µg tissue protein 
is shown. (B) S100A9 protein in skin samples from 
WT and S100A9Tg mice treated with TPA or vehicle 
(acetone). Each lane represents an individual mouse. 
(C) Representative IHC images showing the presence 
of Gr-1+ cells in skin. Bar, 100 µm. (D) The number 
of Gr-1+ cells per square millimeter of skin tissue. 
(E) Phenotype of myeloid cells accumulated in skin 
of TPA-treated mice. Representative flow cytometry 
plots are shown with numbers indicating percent-
age of gated cells. Bar graph on the right illustrates 
the proportions of cell populations. (F and G) The 
number of F4/80+ (F) and CD11c+ (G) cells in skin 
of mice treated with TPA or acetone as indicated. 
(H and I) Proportion (left) and absolute number 
(right) of Gr-1+CD11b+ (H) and Ly6C/Ly6G ratio 
within the population of CD11b+ cells (I) in BM of 
TPA-treated mice. (D–I) Each group included four mice. 
Mean and SD are shown. *, P < 0.05; **, P < 0.01.
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untreated S100A9Tg mice had a low level of the protein, and 
TPA treatment of S100A9Tg mice caused a substantial 
increase in the amount of the protein (Fig. 2 B). Although 
treatment of WT mice with TPA resulted in only a small in­
crease in the number of Gr­1+ cells in skin (evaluated by 
immunohistochemistry [IHC]), in S100A9Tg mice these 
cells increased approximately threefold (P < 0.01; Fig. 2, 
C and D). Evaluation of cells derived from skin sample digests 
by flow cytometry revealed that all the Gr­1+ cells also ex­
pressed CD11b and thus have phenotypic markers of MDSCs. 
The proportion of Ly6ChiLy6G monocytic cells among 
CD11b+ cells in TPA­treated skin was the same in WT and 
S100A9Tg mice, whereas the proportion of Ly6CloLy6G+ 
granulocytic cells was significantly higher in S100A9Tg than 
in WT mice (Fig. 2 E). No differences in the numbers of 
F4/80+ Ms between WT and S100A9Tg skin were found 
(Fig. 2 F), whereas the number of CD11c+ skin DCs was sig­
nificantly lower in both acetone­ and TPA­treated S100A9Tg 
than in WT mice (Fig. 2 G). We investigated whether the dra­
matic increase of granulocytic cells in the skin of S100A9Tg 
mice was the result of their expansion in BM. There was a 
slight increase in the presence of these cells in BM of TPA­
treated S100A9Tg versus WT mice, but the ratio between 
granulocytic and monocytic subsets of IMCs was the same 
(Fig. 2, H and I). These data indicate that, consistent with 
previous observations (Cheng et al., 2008), the overexpression 
of S100A9 in myeloid progenitors did not cause expansion of 
myeloid cells but rather diverted their differentiation toward 
immature granulocytic cells. As a result, topical application of 
TPA in S100A9Tg mice caused substantial accumulation 
of IMCs with granulocytic phenotype, whereas the presence 
of Ms and DCs was either unchanged or decreased.
To study skin carcinogenesis, the S100A9Tg mice were 
crossed with homozygous Tg.AC mice, and hemizygous 
monotransgenic (Tg.AC) and bitransgenic (S100A9; Tg.AC) 
littermates were topically treated twice weekly for 6 wk with 
the tumor promoter TPA. Papillomas developed much faster 
and at significantly (P < 0.001) higher numbers in bitrans­
genic mice expressing S100A9Tg than in monotransgenic 
mice (Fig. 3 A). S100A9 expression could be induced in ke­
ratinocytes under inflammatory conditions (Sorenson et al., 
2012). To clarify the role of infiltrating BM­derived cells in 
increased tumorigenesis in S100A9Tg mice, lethally irradi­
ated Tg.AC mice were reconstituted with BM from WT or 
S100A9Tg mice, and papilloma formation was similarly eval­
uated after TPA treatment. Recipients of S100ATg BM 
developed significantly (P < 0.05) more papillomas than re­
cipients of BM from WT mice (Fig. 3 B), demonstrating that 
up­regulation of S100A9 in BM­derived hematopoietic cells 
was responsible for increased tumor formation. To confirm a 
specific role of IMCs in tumor development, Gr­1+ cells 
were depleted in Tg.AC mice with Gr­1 antibody during the 
first 3 wk of TPA treatment. This treatment significantly 
(P < 0.05) reduced papilloma formation (Fig. 3 C). To evalu­
ate the direct effect of accumulation of IMCs on prolifera­
tion of keratinocytes, WT and S100A9Tg mice were treated 
Figure 3. IMCs enhance papilloma formation. (A) Papilloma develop-
ment in Tg.AC and S100A9Tg;Tg.AC bitransgenic mice after TPA treatment 
for 6 wk. Each group included seven mice. Two-way ANOVA, P = 0.0071.  
(B) Papilloma development in lethally irradiated Tg.AC mice that received 
BM from S100A9Tg or WT (control) mice. TPA treatment started 3 wk  
after the BM transfer. Each group included four mice. Two-way ANOVA,  
P = 0.035. (C) Papilloma development in S100A9Tg;Tg.AC mice treated with 
Gr-1 antibody and TPA as indicated in the graph. Each group included five 
mice. Two-way ANOVA, P < 0.001. (A and C) Mean and SD of the number of 
papillomas per mouse are shown. (D) Proliferation of keratinocytes in WT 
and S100A9Tg FVB/n mice treated for 5 wk with TPA. The proportion of 
proliferating Ki67+ cells among all cytokeratin 14+ keratinocytes was calcu-
lated in at least 100 cells. Each group included three mice. *, P < 0.05  
between TPA- and acetone-treated WT mice; ##, P < 0.01 between  
TPA-treated WT and S100A9Tg mice. (B and D) Mean and SD are shown.
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were found in the numbers of papillomas between WT and 
S100A9KO mice recipients treated with DMBA followed 
by TPA (Fig. 4 E). Collectively, these data demonstrate that 
development of skin tumors directly depends on the accu­
mulation of granulocytic IMCs in the skin. Next we investi­
gated the mechanism or mechanisms by which IMCs mediated 
tumor promotion.
Accumulation of IMCs in skin did not result  
in immune suppression
We tested the hypothesis that IMCs accumulated in TPA­
treated S100A9Tg skin had immune­suppressive activity and 
thus could be defined as MDSCs. S100A9Tg mice were back­
crossed for nine generations to C57BL/6 mice. Mice were 
treated for 6 wk with topical application of TPA. Ly6G+ 
granulocytic IMCs were isolated from the skin and were 
co­cultured with splenocytes from OT­1 mice stimulated 
with control or specific peptides. In contrast to the cells with 
the same phenotype isolated from spleens of tumor­bearing 
mice (MDSCs), skin­infiltrating granulocytic cells from 
TPA­treated mice did not suppress antigen­specific T cell 
response (Fig. 5 A). Similarly, Gr­1+CD11b+ cells isolated 
from BM of WT and S100A9Tg mice treated with TPA also 
lacked immune­suppressive activity (Fig. 5 B). In contrast, 
cells with the same phenotype isolated from BM of tumor­
bearing mice (MDSCs) demonstrated profound suppressive 
with TPA for 5 wk, and the proportion of proliferating ke­
ratinocytes (cytokeratin 14+Ki67+ cells) was evaluated. TPA 
treatment caused proliferation of keratinocytes in WT mice, 
which was significantly (P < 0.01) enhanced in S100A9Tg 
mice (Fig. 3 D).
To better ascertain the possible role of IMCs in tumor 
development, we also used mice with targeted deletion of 
S100A9 (S100A9KO mice, C57BL/6 background; Manitz 
et al., 2003). In contrast to FVB/N mice, untreated WT 
C57BL/6 mice had traces of S100A9 protein in the skin, 
which was increased after 4 wk of TPA treatment (Fig. 4 A). 
S100A9KO mice had no detectable S100A9 protein in the 
skin (Fig. 4 A). Treatment of WT C57BL/6 mice with TPA 
greatly increased the number of Gr­1+ myeloid cells in the 
skin, whereas in S100A9KO mice, this increase was very 
modest and lower than in WT mice (Fig. 4 B). In contrast 
to S100A9Tg mice, S100A9KO mice developed signifi­
cantly (P < 0.01) fewer skin tumors than their WT C57BL/6 
counterparts after treatment with both DMBA and TPA 
(Fig. 4 C). Furthermore, mice reconstituted with BM from 
S100A9KO mice had significantly (P < 0.01) fewer lesions 
than mice reconstituted with WT BM (Fig. 4 D), confirming 
the critical role of BM­derived cells in modulating skin 
tumorigenesis. To further verify a specific role of BM­derived 
cells in tumor development, WT and S100A9 KO mice 
were reconstituted with BM from WT mice. No differences 
Figure 4. Lack of IMCs prevents tumor 
formation. (A) S100A9 protein in skin of 
C57BL/6 WT and S100A9KO mice treated 
with TPA or acetone vehicle. Each lane repre-
sents an individual mouse. Splenocytes from 
a tumor–bearing mouse were used as a posi-
tive control (PC). RP, recombinant protein. 
(B) The number of Gr-1+ cells in skin of 
C57BL/6 mice evaluated by IHC. Mice were 
treated with TPA or acetone for 4 wk. Each 
group included four mice. **, P < 0.01. (C) The 
number of papillomas in WT and S100A9KO 
C57BL/6 mice induced by DMBA and TPA as 
indicated. Each group included seven mice. 
P = 0.003. (D) Number of papillomas in le-
thally irradiated C57BL/6 mice that received 
BM from S100A9KO or WT (control) mice. 
Carcinogen treatment initiated 3 wk after 
the BM transfer. Each group included four 
mice. P < 0.001. (E) Number of papillomas in 
lethally irradiated C57BL/6 WT or S100A9KO 
mice that received BM from WT mice. Car-
cinogen treatment initiated 4 wk after the 
BM transfer. Each group included four mice 
(P > 0.1). (B–E) Mean and SD are shown.
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Figure . IMCs lack suppressive activity. (A) Suppressive activity of Gr-1+ cells isolated from skin of S100A9Tg C57BL/6 mice treated for 6 wk with 
TPA. IMCs were added to splenocytes from OT-1 mice at the indicated ratios. Cells were incubated for 3 d in the presence of specific (SIINFEKL) or control 
(gp100) peptide. Proliferation was measured in triplicates by [3H]thymidine incorporation. Each experiment included three mice. (right) Antigen-specific 
suppressive assay with Gr-1+ MDSCs isolated from spleens of EL-4 tumor-bearing mice. Mean and SD are shown. **, P < 0.01 from no MDSC control. 
(B) Suppression activity of Gr-1+CD11b+ IMCs isolated from BM of mice treated with TPA. Allogeneic mixed lymphocyte reactions were performed using 
CD3-depleted irradiated FVB/N splenocytes as stimulators and BALB/c T cells as responders, mixed at 1:1 ratio. IMCs were added to the mix at the indi-
cated ratios. Proliferation was measured in triplicates by [3H]thymidine incorporation (n = 3). Mean and SD are shown. (C) The phenotype of DCs isolated 
from skin of TPA-treated WT and S100A9Tg mice. Each group included four mice. Mean and SD are shown. ***, P < 0.001. (D) LCs in epidermis of mice. 
(top) Representative image of LCs. Bars, 50 µm. (bottom) Bar graph shows cumulative result of the number of LCs per 1 mm2 of epidermis. Each group 
included four mice (mean and SD are shown). **, P < 0.01. (E) Migration of skin DCs to draining LNs. Dorsal shaved skins of WT and S100A9Tg mice previ-
ously treated with acetone or TPA were painted with DDAO, and 24 h later DDAO+CD11c+ cells were evaluated in draining LNs by flow cytometry. Each 
experiment was performed three times. Mean and SD are shown. *, P < 0.05. (F) T cells from OT1 mice were labeled with DDAO fluorescent dye and  
injected i.v. into TPA-treated WT and S100A9Tg C57BL/6 mice. OVA was applied to the skin 24 h later, and LNs and CD8+CD45.1+ T cell spleens were evalu-
ated by flow cytometry 3 d after the application. A typical example of the CD8+CD45.1+ T cell proliferation is shown on the left, and cumulative results 
(mean ± SD) of three mice in each group are shown on the right.
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activity (Fig. 5 B). Because S100A9Tg mice had reduced 
presence of CD11c+ DCs in the skin as compared with WT 
mice, we analyzed in more detail the different populations of 
DCs in skin by flow cytometry. Only slight differences 
between WT and S100A9Tg mice were seen in the propor­
tion of subsets of skin DCs (Fig. 5 C), with the exception of 
CD207+CD11bCD103+ DCs, which were significantly ele­
vated in S100A9Tg mice compared with WT mice (Fig. 5 C). 
S100A9Tg had a modestly (P < 0.01) reduced number of 
Langerhans cells (LCs) in epidermis (Fig. 5 D). To determine 
whether those changes would translate into decreased migra­
tion of DCs to draining LNs, WT and S100A9Tg mice were 
treated topically with acetone vehicle or TPA for 4 wk, after 
which the skin was painted with fluorescent dye DDAO. 
The next day, skin­draining LNs were collected and DDAO+ 
DCs were counted. We found significantly lower numbers of 
DDAO+CD86+IAbright migratory DCs in LNs of S100A9Tg 
mice than in WT mice (Fig. 5 E).
We wondered whether reduction in DC numbers and 
migration in S100A9Tg skin could result in impaired priming 
of CD8+ T cells. DDAO­labeled OVA­specific OT­1 T cells 
were transferred to WT or S100A9Tg C57BL/6 mice pre­
treated for 4 wk with TPA. OVA protein was applied to the 
same part of the skin as TPA, and 3 d later, proliferation of 
OT­1 T cells was evaluated in LNs and spleen. Robust pro­
liferation of OT­1 cells was observed in all mice. No differ­
ences were found between WT and S100A9Tg mice (Fig. 5 F). 
These results indicate that despite reduced presence of DCs in 
the skin, antigen­specific response was unaffected in S100A9Tg 
mice. Together with the data indicating lack of immune­ 
suppressive activity of IMCs, this finding suggests that im­
mune suppression is not the primary reason for increased tumor 
formation in S100A9Tg mice.
IMCs recruit CD4+ T cells to the skin
We evaluated the presence of lymphocytes in the skin of 
vehicle­ and TPA­treated mice. No significant differences 
between WT and S100A9Tg mice were found in the pres­
ence of B lymphocytes, NK cells, or CD8+ T cells (not de­
picted). In contrast, treatment with TPA resulted in the marked 
accumulation of CD4+ T cells in the skin that was signifi­
cantly (P < 0.01) higher in S100A9Tg mice than in WT mice 
(Fig. 6 A). A small statistically nonsignificant increase was ob­
served in the population of  T cells (Fig. 6 B). Conversely, 
in S100A9KO mice, TPA only caused a modest increase in 
skin CD4+ T cells as compared with the prominent accumu­
lation observed in WT C57BL/6 mice (Fig. 6 C). Skin CD8+ 
T cells in both WT and S100A9KO mice were comparably 
low and unaffected by TPA treatment (not depicted).
The characteristics of CD4+ T cells in skin of TPA­
treated mice were studied using flow cytometry. Consistent 
with the data obtained by IHC, the proportion of CD4+  
T cells among hematopoietic CD45+ cells in skin was signifi­
cantly (P < 0.001) higher in S100A9Tg mice than in WT 
mice (Fig. 6 D). The prevalence of different subsets within 
the population of CD4+ T cells in skin was measured using 
intracellular cytokine staining. No substantial differences 
were found between WT and S100A9Tg mice in the propor­
tion of most CD4+ T cell populations. However, S100A9Tg 
skin showed higher proportions of IL­22+ and IL­10+ cells 
and FoxP3+CD4+ T reg cells and a significantly lower pro­
portion of IL­13+CD4+ cells than WT skin (Fig. 6 E). No 
differences were seen between WT and S100A9Tg skin 
treated with acetone vehicle alone (not depicted). It was pos­
sible that although the proportion of cytokine­producing 
CD4+ T cells was not changed, the level of cytokine produc­
tion on a per cell basis could be different. However, no dif­
ferences were found in the fluorescence intensity of those 
cytokines that showed no changes in the proportion of cells 
(not depicted). To investigate the ability of IMCs to directly 
polarize CD4+ T cells in vitro, naive CD4+CD62L+ T cells 
were co­cultured with IMCs isolated from BM of TPA­
treated WT or S100A9Tg mice. No evidence of CD4+  
T cell polarization was found (Fig. 6 F). Thus, accumulation 
of IMCs in skin of S100A9Tg mice was associated with sub­
stantial increase in the presence CD4+ T cells. Gr­1+ IMCs 
and CD4+ T cells localized in the same vicinity in dermis of 
TPA­treated mice. In contrast,  T cells resided in the dif­
ferent area of the skin (close to epidermis; Fig. 6 G). We 
proposed that although IMCs did not cause specific polariza­
tion of CD4+ T cells, they could recruit a substantial propor­
tion of proinflammatory T cell populations. This hypothesis 
was tested in further experiments.
We investigated whether enhanced tumor formation in 
S100A9Tg mice was mediated by CD4+ T cells. S100A9Tg;Tg.
AC bitransgenic mice were treated with control IgG­ or 
CD4­specific antibody before and during the first 3 wk of 
TPA application. CD4 antibody significantly (P < 0.01) re­
duced the formation of papillomas in these mice (Fig. 7 A), 
indicating that the tumor­promoting effect of IMCs is me­
diated via recruitment of CD4+ T cells. We asked whether 
depletion of CD4+ T cells could affect TPA­inducible accu­
mulation of IMCs in skin. To address this question, the pres­
ence of CD4+ T cells and Gr­1+ IMCs was evaluated in skin 
of mice treated with TPA and CD4 antibody for 5 wk. This 
treatment resulted in abrogation of CD4+ T cell accumula­
tion but did not affect Gr­1+ cells (Fig. 7 B).
Because IMCs attracted a large number of CD4+ to the 
skin, even without causing preferential recruitment of T cell 
populations, the total number of proinflammatory CD4+  
T cells in the skin would substantially increase. We asked 
whether the levels of cytokines produced by CD4+ T cells 
were different in skin of S100A9Tg and WT mice. The 
cytokines were also measured in spleen and BM, where no 
significant changes in myeloid or lymphoid cells were ob­
served. No differences were found in the amount of IL­10 or 
IL­22 between TPA­treated WT and S100A9Tg mice. In 
contrast, the amount of IL­17A was significantly higher in 
the skin but not spleen and BM of S100A9Tg mice than 
in WT mice (Fig. 7 C). CD4+ T cells appear to play a major 
role in IL­17A accumulation in skin because depletion of 
CD4+ T cells abrogated TPA­inducible increase in IL­17A in 
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Figure . IMCs recruit CD4+ T cells to the skin. (A) The number of CD4+ T cells in the skin of WT and S100A9Tg FVB/N mice. The number of cells was 
evaluated by IHC and counted per square millimeter of tissue. Each experiment included five mice. (B) The number of  T cells in skin of TPA-treated WT and 
S100A9Tg C57BL/6 mice. The number of cells was evaluated by IHC and counted per square millimeter of tissue (n = 3). (C) The number of CD4+ T cells in the 
skin of WT and S100A9KO C57BL/6 mice evaluated by IHC and counted per square millimeter of tissue. Each experiment included five mice. (D) The proportion 
of CD4+ cells among CD45+ hematopoietic cells in WT and S100A9Tg mice treated with TPA and evaluated by flow cytometry. Six mice per group. (E) Intra-
cellular staining of different cytokines in cells isolated from the skin of WT and S100A9Tg mice treated with TPA. CD4+ cells were gated. Each group included 
three to six mice. (F) Polarization of naive CD62L+CD4+ T cells by IMCs in vitro. T cells were cultured with BM IMCs from WT and S100A9Tg mice at a 1:1 ratio 
for 4 d in the presence of CD3/CD28 beads. Cells were then stimulated for 4 h with TPA/ionomycin in the presence of GolgiStop. Intracellular cytokines were 
evaluated within the population of CD4+ T cells by flow cytometry (n = 5). (A–F) Mean and SD are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (G) Localiza-
tion of Gr-1+ and CD4+ T cells or  T cells in skin of TPA-treated S100A9Tg mice. Immunofluorescent microscopy with the indicated antibodies is performed. 
Merge staining included DAPI (blue). Typical example of three experiments is shown. Epidermis and dermis are marked with E and D. Please note that to see 
accumulated CD4+ T cells in the skin, the field had to be moved further down and epidermis was outside the area. Bars, 50 µm.
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T cell migration. However, IMCs activated with LPS or 
TPA secreted potent chemotactic activity for CD4+ T cells 
(Fig. 8 A and not depicted). Importantly, chemotaxis of CD4+ 
T cells was observed only if T cells were also stimulated be­
fore the assay (Fig. 8 A). When IMC supernatants were placed 
in both chambers during the assay, CD4+ T cell migration was 
significantly reduced, indicating that the effect was indeed the 
result of chemotaxis (not depicted).
Using RNA isolated from skin, we examined expression 
of chemokines known to be involved in the migration of 
CD4+ T cells. Expression of ccl3 (chemokine [C-C motif] ligand 3) 
and ccl4 RNAs was significantly (P < 0.05) up­regulated in 
the skin of TPA­treated S100A9Tg mice compared with WT 
mice, whereas the expression of ccl22 was modestly increased 
the skin (Fig. 7 D). These data suggested that IL­17 could 
play an important role in IMC­mediated promotion of tumor 
formation. To test this hypothesis, we used IL­17 neutraliz­
ing antibody in C57BL/6 S100A9Tg and WT mice treated 
with DMBA and TPA. Blockade of IL­17 dramatically 
reduced papilloma formation in S100A9Tg mice (Fig. 7 E). 
Thus, accumulation of granulocytic IMCs in skin resulted in 
recruitment of CD4+ T cells and to a lesser extent  T cells 
that could promote tumor development via release of IL­17.
The mechanism of IMC-inducible recruitment of CD4+ T cells
How could IMCs recruit CD4+ T cells? We evaluated the 
ability of IMCs to attract CD4+ cells in vitro. Supernatants 
from normal BM­derived IMCs had no effect on CD4+  
Figure 7. The role of IL-7 in IMC-mediated enhancement of papilloma formation. (A) Papilloma development in CD4-depleted S100A9Tg;Tg.AC 
bitransgenic mice. CD4 antibody or IgG (control) treatment was performed as indicated on the graph. Mean and SD of papillomas per mouse are shown. 
Each group included five mice. Two-way ANOVA, P = 0.021. (B) The presence of CD4+ T cells and Gr-1+ IMCs in skin of C57BL/6 S100A9Tg mice treated 
with TPA and CD4 antibody for 5 wk. Cells were evaluated by IHC (n = 4). (C) The presence of cytokines in tissues of WT and S100A9Tg mice treated with 
TPA for 6 wk. Cytokines were measured in whole cell lysates using ELISA. **, P < 0.01. (D) The amount of IL-17A in skin of mice described in B measured by 
ELISA. (B and D) **, P < 0.01 from acetone-treated mice; #, P < 0.05 from TPA only–treated mice (n = 6). (E) Papilloma formation in S100A9Tg C57BL/6 
mice was induced by DMBA application, followed by 16 wk of treatment with TPA. Mice were treated with 200 µg of either control IgG or neutralizing 
IL-17 antibody during the first 12 wk. Each group included five mice. Two-way ANOVA, P < 0.001. (B–E) Mean and SD are shown.
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CCL4, this chemokine was measured in supernatants from 
BM IMCs isolated from TPA­treated WT and S100A9Tg 
mice. A large amount of CCL4 was found in supernatants 
from stimulated IMCs (Fig. 8 E). Next, we evaluated the na­
ture of stimuli that could induce expression of ccl4 in IMCs 
isolated from BM of naive mice. IMCs were treated for 24 h 
with several proinflammatory cytokines. IFN­ caused more 
than fourfold up­regulation of ccl4 expression. The effect of 
TNF was significant but less potent, whereas IL­1 at a 
selected concentration did not up­regulate ccl4 expression in 
(Fig. 8 B). However, no differences in the amount of CCL3 
and CCL22 proteins were found in skin lysates of TPA­
treated S100A9Tg and WT mice (Fig. 8 C). In contrast, the 
amount of CCL4 in the skin of TPA­treated S100A9Tg mice 
was significantly higher than in WT mice. No differences in 
the amount of CCL4 were observed in spleens, BM, lung, or 
liver (Fig. 8 D). Because skin was the primary site of IMC 
accumulation in TPA­treated S100A9Tg mice, these data 
are consistent with the role of IMCs as the primary source 
of CCL4. To verify that IMCs are indeed able to produce 
Figure . Skin IMCs release CD4+ T cell 
chemokine CCL4. (A) Chemotaxis of CD4+  
T cells isolated from control mice to supernatant 
from IMCs. IMCs were either stimulated or not 
with LPS. T cells were stimulated or not with 
CD3/CD28 antibody. CD4+ T cells were placed in 
the top chamber and supernatants (30% vol/vol) 
in the bottom chamber. For control, LPS was 
added to the medium in the bottom chamber. 
Mean and SD of cumulative results of six inde-
pendent experiments are shown. ***, P < 0.001. 
(B) Quantitative RT-PCR analysis of the expres-
sion of ccl3, ccl4, ccl5, and ccl22 in skin of WT or 
S100A9Tg mice treated with TPA or acetone. 
Differences in expression of ccl3 and ccl4 were 
significant. Mean and SD are shown. *, P < 0.01. 
(C) Amount of CCL22 (left) and CCL3 (right) 
protein measured by ELISA in lysates of various 
organs from TPA-treated WT and S100A9Tg 
mice. Mean and SD from four experiments with 
three mice per group are shown. Each measure-
ment was performed in duplicate and normal-
ized for total protein. Cumulative results from 
three experiments are shown. (D) Amount of 
CCL4 protein measured by ELISA in lysates  
of various organs from TPA-treated WT and 
S100A9Tg mice. Mean and SD from four experi-
ments with three mice per group are shown. 
Each measurement was performed in dupli-
cate normalized for total protein. **, P < 0.01. 
(E) Amount of CCL4 determined by ELISA in 
supernatants of IMCs isolated from BM of WT or 
S100A9Tg mice treated with TPA for 4 wk. Cells 
were activated with LPS overnight. Measure-
ments were performed twice in duplicates. Mean 
and SD are shown. (F) Expression of ccl4 in 
Gr-1+CD11b+ IMCs isolated from BM of naive 
mice treated for 24 h with the indicated cyto-
kines. The range of most commonly used con-
centrations was tested. Concentrations 
shown: 250 ng/ml IFN-, 50 ng/ml TNF,  
50 ng/ml IL-1, and 100 ng/ml LPS. Ccl4 ex-
pression was measured by quantitative PCR 
and normalized to -actin. Mean and SD are 
shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001 
from control (n = 3). (G) Expression of ccl4 in 
Gr-1+ and Gr-1 cells isolated from skin of 
WT or S100A9Tg mice treated for 5 wk with 
TPA (n = 3). Mean and SD are shown.
 o
n
 February 10, 2015
jem.rupress.org
D
ow
nloaded from
 
Published February 9, 2015
2 of 7 Immature myeloid cells and tumor development | Ortiz et al.
were performed in S100A9Tg;Tg.AC bitransgenic mice who 
developed higher numbers of papillomas than Tg.AC mice, 
but the CCL4 antibody still drastically (P < 0.01) reduced the 
number of tumors (Fig. 9 E).
DISCUSSION
In this study, we report, for the first time, that granulocytic 
IMCs directly contribute to skin tumor development via 
recruitment of IL­17–producing CD4+ T cells (Th17 cells). 
Although the link between inflammation and cancer is well 
established (Arthur et al., 2012; Coussens et al., 2013), the 
contribution of specific cell populations to the initial phase of 
tumor development remains unclear. Previously, Ms were 
shown to be involved in early stages of tumor development 
and progression (Hagemann and Balkwill, 2005; Sica and 
Bronte, 2007; Schmid and Varner, 2012). The role of MDSCs 
in tumor immune escape is now well established. In recent 
years, evidence pointed to expansion of MDSCs in chronic 
infection and inflammation (Cuenca et al., 2011; Nagaraj 
et al., 2013). This increase in MDSCs raised the question 
as to whether these cells could contribute to tumorigenesis. 
Our data demonstrated accumulation of a large number of 
CD33+S100A9+ cells (the phenotype typical for MDSCs) in 
IMCs (Fig. 8 F). We assessed the expression of ccl4 in cells 
isolated directly from skin of WT or S100A9Tg mice. Skin 
Gr­1+ IMCs from TPA­treated WT or S100A9Tg mice 
expressed a high level of ccl4, whereas no expression was 
detected in Gr­1 cells (Fig. 8 G).
To verify the role of CCL4 in CD4+ T cell recruitment 
by Gr­1+ myeloid cells, we added neutralizing CCL4 anti­
body to IMC supernatants in chemotaxis assay. CCL4­specific 
antibody abrogated CD4+ T cell migration caused by IMCs 
in a dose­dependent manner (Fig. 9 A). To test the role of 
CCL4 in vivo, WT and S100A9Tg mice were treated for 
4 wk with control or CCL4 antibody concurrent with TPA. 
Treatment with CCL4 antibody did not affect the presence 
of Gr­1+ myeloid cells or CD8+ T cells in the skin (not 
depicted). In contrast, neutralization of CCL4 significantly 
(P < 0.01) reduced the presence of CD4+ T cells in WT and 
S100A9Tg skin (Fig. 9 B). CCL4 antibody significantly re­
duced the presence of IL­17A in the skin of S100A9Tg mice, 
strongly suggesting the link between CCL4­mediated CD4+ 
T cell migration and IL­17A presence in the skin (Fig. 9 C). 
Weekly treatment of Tg.AC mice with CCL4 antibody dur­
ing the first 3 wk of TPA promotion significantly reduced the 
formation of tumors (P < 0.01; Fig. 9 D). Similar experiments 
Figure 9. CCL4 is responsible for the recruitment of CD4+ T cells to the skin. (A) Neutralizing CCL4 antibody inhibited migration of activated 
CD4+ T cells toward supernatant obtained from LPS-stimulated IMCs. Concentrations of CCL4 antibody or IgG are shown in the graph. Two experiments 
were performed in duplicate. (B) S100A9Tg mice were treated for 4 wk with TPA and either control IgG or neutralizing CCL4 antibody. The number of 
CD4+ cells in the skin is shown. (C) The amount of IL-17A in the skin of S100A9Tg mice treated with CCL4 antibody. Each group included three mice.  
(A–C) Mean and SD are shown. *, P < 0.05; **, P < 0.01. (D and E) The number of papillomas formed in Tg.AC (D) and S100A9Tg;Tg.AC (E) mice treated  
with TPA and control IgG or CCL4 antibody as indicated. Mean and SD are shown. Each group included four mice. P = 0.001 (D) and P < 0.001 (E).
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papilloma formation. We found that granulocytic IMCs 
recruited CD4+ T cells to the site of their accumulation. Im­
portantly, only activated IMCs were able to recruit CD4+  
T cells. Our data indicated that IMCs did not specifically re­
cruit Th17 CD4+ T cells or cause their conversion from pre­
cursors, but rather recruited these cells as part of large pool of 
CD4+ T cells. It was associated with dramatic decrease in IL­
13–producing CD4+ T cells. IL­13 was previously shown to 
be a negative regulator of Th17 cells (Newcomb et al., 2009). 
This resulted in significant increase of IL­17 but not IL­22 
in the skin of S100A9Tg mice as compared with WT mice. 
Depletion of CD4+ T cells or IL­17 in S100A9Tg mice ab­
rogated induction of papilloma formation. These data strongly 
indicate that CD4+ T cells and IL­17 mediated the effect of 
IMCs on tumor development.
The role of CD4+ T cells in tumor progression remains 
enigmatic and thus requires further investigation. The CD4+ 
T cell deficiency on one hand enhanced cancer progression 
in methylcholanthrene (MCA)­initiated sarcoma development 
(Koebel et al., 2007; DeNardo et al., 2010), whereas on the 
other hand, it inhibited tumor development in the two­stage 
squamous carcinogenesis model (Girardi et al., 2003). Sim­
ilarly, in the K14HPV16 skin cancer model, with E6/E7 
oncogenes expressed in epidermis from keratin 14 promoter, 
CD4+ T cell deficiency modestly attenuated neoplastic pro­
gression, whereas cervical carcinoma development was sig­
nificantly enhanced (Daniel et al., 2003, 2005). However, 
there are studies suggesting that IL­17 and IL­22 produced by 
Th17 cells contribute to tumor development by inducing an­
giogenesis or directly affecting keratinocyte proliferation and 
survival (Heidenreich et al., 2009; Cho et al., 2012; Fujita, 
2013). IL­17 also promotes accumulation of cells with MDSC 
phenotype (He et al., 2010), suggesting a feedback mecha­
nism. IL­17 KO mice in a two­stage carcinogenesis model 
showed delayed papilloma formation compared with WT mice 
(Xiao et al., 2009; Wang et al., 2010).
We identified CCL4 chemokine as the main factor 
responsible for IMC­mediated recruitment of CD4+ T cells. 
CCL4 or MIP­1 is a 69­aa member of the  (CC) family 
of chemokines. It is produced by various cells, including 
myeloid cells, and binds to CCR1, CCR5, and US28 recep­
tors. Melanoma­associated MDSCs produce high levels of 
CCL4 among other chemokines, and in CCR5­deficient mice 
growth of transplantable tumors was delayed (Schlecker et al., 
2012). Activated CD4+ T cells up­regulate CCR5 receptor, 
allowing these cells to be recruited to the site of CCL4 pro­
duction (Castellino et al., 2006), which is consistent with our 
finding that IMCs attracted only activated CD4+ T cells. Al­
though it was reported that different CD4+ T cell subsets may 
express unique repertoires of chemokine receptors, current 
evidence suggests that CCR5 can be expressed on recently 
activated cells of any subset (Bromley et al., 2008), consistent 
with lack of preferential accumulation of specific populations 
of CD4+ T cells in the skin of S100A9Tg mice.
Our data suggest a sequence of events that promote tumor 
formation in skin and possibly other tissues. Granulocytic 
tissues of patients with inflammatory conditions, which pre­
disposes to the development of cancers. Accumulation of these 
cells was more prominent than that of mature neutrophils 
and Ms.
Because inflammation is a complex process, the specific 
role of individual cell populations in tumor promotion is dif­
ficult to ascertain. S100A9Tg mice provide a novel experi­
mental model in which tissue accumulation of cells with the 
IMC phenotype is not caused by infection, trauma, or can­
cer. The vast majority of myeloid cells accumulated in skin 
of S100A9Tg were granulocytic IMCs, which is consistent 
with the concept that overexpression of S100A9 in myeloid 
precursors inhibits differentiation of myeloid precursors to 
DCs, and to some extent Ms, and promotes appearance of 
immature granulocytes. Activated keratinocytes can attract 
granulocytes via release of CXCL8 chemokine (Huang et al., 
2011). This chemokine may provide a signal for initial influx 
of IMCs to TPA­treated skin. Our results with BM trans­
fers and Gr­1–specific antibody depletions in S100A9Tg 
mice, as well as decreased skin carcinogenesis in S100A9KO 
mice, demonstrate that IMCs were the primary facilitator of 
tumor development in this experimental system. Our data in 
S100A9KO mice are not consistent with a recent study indi­
cating that S100A9 had a protective role in inflammation­ 
induced skin carcinogenesis (McNeill and Hogg, 2014). 
Whether differences were caused by differences in the mouse 
models or other factors needs to be elucidated. IMCs accu­
mulated in skin of mice lack immune­suppressive activity and 
thus cannot be defined as MDSCs. These results were consis­
tent with recent findings of accumulation of myeloid cells 
with a phenotype similar to that of MDSCs but lacking 
immune­suppressive activity in mice exposed to cigarette smoke 
(Ortiz et al., 2014). These cells acquired immune­suppressive 
activity only after the development of lung tumors (Ortiz 
et al., 2014). Our data demonstrated that although the num­
ber of DCs migrating from skin to LN in S100A9Tg mice 
was decreased, the priming of CD8+ T cells to antigen ap­
plied over the skin was not affected. Apparently, the modest 
decrease in DCs in skin was not sufficient to inhibit CD8+  
T cell priming. Alternatively, the significantly higher propor­
tion of CD11bCD207+CD103+ DCs in S100A9Tg mice 
may have compensated for decrease of other DC subsets 
because these cells play a major role in cross­presentation of 
antigens in the skin (Henri et al., 2010). Collectively, these 
data indicate that enhanced papilloma formation in S100A9Tg 
mice is not caused by myeloid cell–mediated immune sup­
pression as typically observed with MDSCs in cancer.
Granulocytic cells may contribute to neoplastic transfor­
mation by increasing the rate of mutation and proliferation of 
epithelial cells via release of reactive oxygen species (Marnett, 
2000; Le’Negrate et al., 2003; Balkwill, 2009), activation of 
cyclooxygenase­2 (Kim et al., 2005), and inhibition of nucle­
otide excision repair by myeloperoxidase (Gasche et al., 2001; 
Hofseth et al., 2003; Güngör et al., 2007). In this study, we 
did not evaluate the malignant conversion of tumor lesions 
but focused on the earlier premalignant events promoting 
 o
n
 February 10, 2015
jem.rupress.org
D
ow
nloaded from
 
Published February 9, 2015
4 of 7 Immature myeloid cells and tumor development | Ortiz et al.
described (Gebhardt et al., 2008). Papillomas were assessed weekly and counted 
when they reached 1 mm for at least 2 wk. In BM transfer experiments, le­
thally irradiated (950 rads) mice were injected i.v. with 106 BM cells from 
donor mice. Treatment with TPA or DMBA plus TPA as described above was 
started 3 wk after the BM transfer.
Tissue preparation and histology. Skin pieces were snap­frozen, and 
slides were fixed with acetone and blocked overnight with 10% goat serum, 
1% BSA, and 2.5% mouse serum in PBS at room temperature. The primary 
antibodies from BD were used at 1:100 dilutions: Gr1 (RB6­8C5), CD4 
(H129.19), and CD8 (53­6.7). The antibodies from eBioscience were used 
at 1:50 dilution: CD11c (N418) and F4/80 (BM8). Biotinylated anti–rat IgG 
(Vector Laboratories) or anti–hamster IgG (Vector Laboratories) was used as 
a secondary antibody. Alkaline phosphatase kit and Vector Red substrate 
(Vector Laboratories) were used for visualization of the results. The tissues 
were counterstained with hematoxylin. Images were taken by the digital slide 
scanner Scanscope (Aperio) and analyzed by Aperio software. Cell number 
was calculated per 1 mm2. The antibodies specific for  T cells (GL­3), cy­
tokeratin­14 (LL002), and Ki67 (SP6) were purchased from Abcam, and the 
staining was evaluated on an E600 upright microscope.
Cytokine expression. For the analysis of gene expression, total RNA was 
extracted with TRIzol reagent (Invitrogen), and cDNA was synthesized 
using the High Capacity cDNA Reverse transcription kit (Applied Biosys­
tems). To detect chemokines, PCR was performed with 2 µl cDNA and 
12.5 µl SYBR Master Mixture (Applied Biosystems) using specific primers: 
Ccl2, 5­CCCAATGAGTAGGCTGGAGA­3 and 5­AAAATGGATCCAC­
ACCTTGC­3; Ccl3, 5­CCAAGTCTTCTCAGCGCCATA­3 and 
5­GATGAATTGGCGTGGAATCTTC­3; Ccl4, 5­TGCTCGTGG­
CTGCCTTCT­3 and 5­CTGCCGGGAGGTGTAAGAGA­3; Ccl5, 
5­TGCCCACGTCAAGGAGTATT­3 and 5­CAGGACCGGAGT­
GGGAGTA­3; Ccl9, 5­GATGAAGCCCTTTCATACTGC­3 and 
5­GTGGTTGTGAGTTTTGCTCCAATC­3; and Ccl22, 5­GTGGC­
TCTCGTCCTTCTTGC­3 and 5­GGACAGTTTATGGAGTAGCTT­3. 
Amplification of endogenous ­actin was used as an internal control.
For evaluation of the proteins, tissues were homogenized in RIPA buf­
fer, and BM cells were flushed out for protein extraction. Chemokines were 
measured by ELISA using the kits from PeproTech: CCL3, CCL4, or 
CCL22. CCL4 was also measured using an R&D Systems kit. Likewise, the 
cytokines (IL10, IL17A, and IL22) in skin, spleen, and BM were measured 
by ELISA using the kits from eBioscience.
Western blot. Samples (30 µg protein per lane) were subjected to electro­
phoresis in 12% SDS­polyacrylamide gels and then blotted onto PVDF 
membranes. Membranes were blocked for 1 h at room temperature with 5% 
dry skim milk in TBS (20 mM Tris­HCl, pH 7.6, and 137 mM NaCl plus 
0.1% [vol/vol] Tween 20) and then probed with S100A9 or ­actin–specific 
antibodies (Santa Cruz Biotechnology, Inc.), followed by secondary anti­
body conjugated with horseradish peroxidase. Results were visualized by 
chemiluminescence detection (GE Healthcare).
Depletion of cells and neutralization of chemokines in vivo. Mice 
were injected i.p. with 250 µg CD4 (clone: GK1.5; Bio X Cell) and Gr­1 
(clone: RB6­8C5; Bio X Cell). Injections were performed once a week for 
4 wk starting 1 wk before the beginning of TPA treatment. For neutralization 
of CCL4 and IL17A, 100 µg CCL4 (R&D Systems)­ or 200 µg IL­17A (clone: 
17F3; Bio X Cell)–specific monoclonal antibodies were used. Control groups 
in CD4 and Gr­1 depletion and neutralization experiments received rat 
IgG2b isotype (clone: LTF2; Bio X Cell); controls for IL17A neutralization 
experiments received mouse IgG (Sigma­Aldrich), whereas controls in CCL4 
neutralization experiments received goat IgG (R&D Systems).
CD4+ T cell polarization experiments. Naive CD62L+CD4+ T cells 
were isolated from spleen of FVB/N mice using magnetic beads (Miltenyi 
Biotec) and co­culture with Gr­1+ cells isolated from BM of WT or S100A9Tg 
IMCs accumulate at the site of cutaneous irritation or inflam­
mation. Activated IMCs release CCL4 that recruits CD4+  
T cells, including proinflammatory populations. These T cells 
release IL­17 to stimulate proliferation of keratinocytes, which 
contribute to tumor formation. The direct effect of IMCs on 
keratinocytes or epithelial cells in other tissues merits further 
investigation, as well as the possibility that targeting IMCs may 
benefit individuals with high risk of cancer development.
MATERIALS AND METHODS
Patient samples. De­identified colon tissues slides were obtained from 
St. Mark’s Hospital (Harrow, England, UK). Samples were taken from patients 
after obtaining informed consent and with the approval of the Outer West 
London Research Ethics Committee (UK). It included six samples obtained 
from normal colonic biopsies (control), five samples from patients with ul­
cerative colitis showing low­ and high­grade dysplasia, and six samples from 
patients with colorectal cancer (moderately differentiated adenocarcinoma). 
Paraffin­embedded tissue blocks were retrieved using an approved Insti­
tutional Review Board protocol for de­identified archived skin biopsies 
through the Department of Dermatology, National Institutes of Health Skin 
Disease Research Center Tissue Acquisition Core (P30­AR057217), Perelman 
School of Medicine, University of Pennsylvania (Philadelphia, PA). It in­
cluded five samples from normal skin (control), five samples from patients with 
lichen planus, five patients with psoriasis, five patients with spongiotic der­
matitis (eczema), five patients with BCC, and five patients with melanoma.
After deparaffinization, rehydration, and blocking endogenous perox­
ides with fixation with 5% hydrogen peroxide in methanol, heat­induced 
antigen retrieval was performed using Tris­EDTA buffer. For evaluation of 
S100A9+CD33+ cells, tissues were stained with S100A9 antibody (diluted 
1:500 in 5% BSA; Novus Biologicals) and CD33 antibody (dilution 1:100 
in 5% BSA; Novocastra) followed by Alexa Fluor 594 antibody (dilution 
1:400 in 5% BSA; Life Technologies) and Alexa Fluor 647 antibody (dilu­
tion 1:400 in 5% BSA; Life Technologies). For neutrophils and Ms, a 
single staining protocol was used. Neutrophils were stained with neutrophil 
elastase antibody (dilution 1:2,000 in 5% BSA; Abcam) and Ms with 
CD163 antibody (dilution 1:200 in 5% BSA; Abcam). Alexa Fluor 594 (Life 
Technologies) anti–rabbit antibody was used as secondary. Cell nuclei were 
stained with DAPI (dilution 1:5,000 in PBS; Life Technologies). Cells were 
analyzed using a TCS SP5 confocal microscope (Leica) and E600 upright 
microscope (Nikon). The number of cells per square millimeter of tissue 
was calculated in at least five fields using Image pro plus software (Media 
Cybernetics). Positive stained cells were normalized to total nuclear cell 
count using DAPI.
Mice. All animal experiments were approved by the University of South 
Florida Institutional Animal Care and Use Committee. Mice were housed in 
pathogen­free facilities. Tg.AC mice described previously (Tepper et al., 1990) 
were obtained from Taconic. S100A9Tg mice on FVB/N background (Cheng 
et al., 2008) and S100A9KO mice on C57BL/6 background (Manitz et al., 
2003) were described previously. BALB/c, C57BL/6, and FVB/N mice were 
obtained from the National Cancer Institute, and OT­1 mice were obtained 
from the Jackson Laboratory. In S100A9Tg;Tg.AC bitransgenic mice, the 
presence of S100A9­IRES­GFP transgene was verified by the expression 
of GFP in leukocytes from peripheral blood, and the v-h-ras transgene was 
detected by genomic PCR for the SV40 sequences. In some experiments, 
S100A9Tg mice on C57BL/6 background were used after backcrossing 
S100A9Tg FVB/N mice with C57BL/6 mice for nine generations.
Skin carcinogenesis. Female, aged­matched (7–10 wk old) littermate mice 
were used in experiments with Tg.AC and S100A9Tg;Tg.AC mice. Dorsal 
skin was shaved, and 3 nmol TPA (Sigma­Aldrich) in 200 µl acetone vehicle 
was applied twice a week for 4 or 6 wk. In the carcinogenesis model in 
C57BL/6 WT or S100A9KO mice, 100­nmol single dose of DMBA was 
topically applied, followed by 10 nmol TPA every 24 h for 12 wk, as previously 
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For the assessment of in vivo T cell proliferation in response to antigens, 
splenocytes and LN cells collected from OT­1 CD45.1+ mice were labeled 
with 5 µM DDAO. Eight million DDAO­labeled OT­1 cells were injected 
into the tail vein of C57BL/6 (CD45.2+) WT and S100A9Tg mice that 
were pretreated for 4 wk with TPA. The day after transfer, 10 mg OVA 
protein in 500 µl Ultrasicc gel was applied onto the shaved dorsal skin of the 
mice. 3 d later, skin­draining LNs and spleen were collected. Cells were 
stained and analyzed by flow cytometry.
Statistical analysis. Statistical analysis was performed using an unpaired 
two­tailed Student’s t test with significance determined at P < 0.05. For the 
analysis of papilloma formation, statistical significance of repeated measure­
ments was assessed using a two­way ANOVA test.
Support was provided by Wistar Institute imaging and flow cytometry cores.
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